Relevance of Moderate Isolated Thrombopenia as a Strong Predictive Marker of Cirrhosis in Patients With Chronic Hepatitis C Virus

Renou, Christophe; Müller, P; Jouve, Élisabeth; Bertrand, Jean-Jacques; Raoult, Annie; Benderriter, Thierry; Halfon, Philippe

doi:10.1111/j.1572-0241.2001.03830.x

Cited by 23 publications

(14 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The platelet count itself and platelet-related index (the aspartate aminotransferase AST/platelet ratio index or APRI) have been observed to be associated with liver fibrosis/cirrhosis [12,13]. It is thus a critical aspect that the potential effect of hepatic fibrosis on the platelet counts in CHC patients should be controlled before addressing the issue that HCV infection is associated with low platelet counts.…”

Section: Introductionmentioning

confidence: 99%

Hepatitis C virus viremia and low platelet count: A study in a hepatitis B & C endemic area in Taiwan

Dai

Huang

et al. 2010

Journal of Hepatology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Hepatitis C virus viremia and low platelet count: A study in a hepatitis B & C endemic area in Taiwan

Dai

Huang

et al. 2010

Journal of Hepatology

View full text Add to dashboard Cite

“…However, it is an invasive procedure that has been associated with complications, and there are concerns regarding sampling error and inter-and intra-observer variations in interpretation [24][25][26][27][28]. Non-invasive approaches for evaluating the serum markers of fibrogenesis include platelet counts, prothrombin time, the ratio of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, and the level of gamma-glutamyl transpeptidase (GGT) [29][30][31][32][33][34]. The most sensitive and specific markers are hyaluronic acid, type IV collagen, N-terminal propeptide of type III procollagen, metalloproteinases, inhibitors of metalloproteinases, and transforming growth factor beta [35][36][37][38][39][40][41].…”

Section: Introductionmentioning

confidence: 99%

Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: The fibrovic study – ANRS HC02

Cacoub

Carrat

Bédossa

et al. 2008

Journal of Hepatology

Self Cite

View full text Add to dashboard Cite

“…Some rely on routine laboratory tests, easily available in clinical practice. [8][9][10][11][12][13][14] There are only two reported models which have focused on non-invasive diagnosis of liver fibrosis among HIV/HCV coinfected patients. 15 16 However, none of the models has been validated by independent authors in this population.…”

mentioning

confidence: 99%

“…Our aim was to validate five predictive models of liver fibrosis comprising readily available laboratory data, previously constructed and validated in HCV monoinfected patients, [8][9][10][11][12][13][14] in HIV/HCV coinfected patients.…”

mentioning

confidence: 99%

Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes

Macı́as

Girón-González²,

González-Serrano³

et al. 2006

Gut

113

View full text Add to dashboard Cite

Background: Liver biopsy is an invasive technique with associated major complications. There is no information on the validity of five non-invasive indexes based on routinely available parameters, estimated and validated in hepatitis C virus (HCV) monoinfected patients, in human immunodeficiency virus (HIV)/ HCV coinfected patients. Aim: To validate these predictive models of liver fibrosis in HIV/HCV coinfected patients. Patients: A total of 357 (90%) of 398 patients from five hospitals were investigated, who underwent liver biopsy and who had complete data to validate all of the models considered. Methods: The predictive accuracy of the indexes was tested by measuring areas under the receiver operating characteristic curves. Diagnostic accuracy was calculated by estimating sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values. Results: The models performed better when liver biopsies >15 mm were used as reference. In this setting, the Forns and Wai indexes, models aimed at discriminating significant fibrosis, showed PPV of 94% and 87%, respectively. Using these models, 27-34% of patients could benefit from exclusion of liver biopsy. If both models were applied sequentially, 41% of liver biopsies could be spared. The indexes aimed at predicting cirrhosis achieved NPV of up to 100%. However, they showed very low PPV. Conclusions: The diagnostic accuracy of these models was lower in HIV/HCV coinfected patients than in the validation studies performed in HCV monoinfected patients. However, simple fibrosis tests may render liver biopsy unnecessary in deciding anti-HCV treatment in over one third of patients with HIV infection and chronic hepatitis C.

show abstract

Relevance of Moderate Isolated Thrombopenia as a Strong Predictive Marker of Cirrhosis in Patients With Chronic Hepatitis C Virus

Cited by 23 publications

References 8 publications

Hepatitis C virus viremia and low platelet count: A study in a hepatitis B & C endemic area in Taiwan

Hepatitis C virus viremia and low platelet count: A study in a hepatitis B & C endemic area in Taiwan

Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: The fibrovic study – ANRS HC02

Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes

Contact Info

Product

Resources

About